TERT promoter mutations were more frequent in age ≥ 55 years (p < 0.001), male sex (p < 0.001), larger tumor size (p < 0.001), multifocal PTCs (p = 0.020), extrathyroidal extension (p < 0.001), perinodal infiltration (p < 0.001), T3–4 (p < 0.001)/M1 (p < 0.001) stages, stage III–IV (p < 0.001), and more adjuvant RAI therapy (p < 0.001). This evidence concerns the gene TERT and neoplasm.